| 恶心呕吐 | 30.4% | 0 | 36.4% | 0 | 0.673 |
|
| 腹泻 | 0 | 0 | 0 | 0 |
| |
| 变态反应 | 0 | 0 | 0 | 0 |
| |
| 体温升高 | 34.8% | 0 | 27.3% | 0 | 0.586 | |
| 疼痛 | 17.4% | 8.7% | 18.2% | 4.5% | 0.856 | |
| 肝功能损伤 | 26.1% | 17.4% | 22.7% | 9.1% | 0.644 | |
| 肾功能损伤 | 0 | 0 | 0 | 0 |
| |
| 骨髓抑制 | 21.7% | 0 | 18.2% | 0 | 0.766 | |
| ASCO评分 | 5 | 4 | 5 | 3.5 |
| |
| 额外获益 |
|
|
| 13.58/60 | ||
| 曲线终点 | 0 |
|
|
| ||
| 症状改善 | 10 |
|
|
| ||
| 生活质量 | 0 |
|
| |||
| 无治疗缓解期 | 3.58 |
|
| |||
| 净健康获益 | 53.4/180 | |||||